Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history?

International Braz J Urol

Volumn 36, Issue 5, 2010, Pages 571-581

  Sexton, Wade J ^a   Spiess, Philippe E ^a   Pisters, Louis L ^b   Carpenter, Scott ^b   Madsen, Lydia T ^b   Zagone, Robin ^b   Wang, Xuemei ^b   Troncoso, Patricia ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Family characteristics; Pathology; Prostatic neoplasms; Tumor burden; Tumor volume

Indexed keywords

AGE; ARTICLE; CANCER STAGING; ETHNOLOGY; FAMILY SIZE; GENETICS; HUMAN; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; SOCIOECONOMICS; STATISTICAL MODEL; TUMOR VOLUME; UNITED STATES;

AGE FACTORS; FAMILY CHARACTERISTICS; HUMANS; LOGISTIC MODELS; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; SOCIOECONOMIC FACTORS; TUMOR BURDEN; UNITED STATES;

EID: 78650195243     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382010000500007     Document Type: Article

References (25)

1. Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ: Clinical and pathological features of hereditary prostate cancer. J Urol. 1996; 155: 1841-3.
2. Bratt O, Kristoffersson U, Lundgren R, Olsson H: Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer. 1999; 35: 272-7.
3. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC: Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A. 1992; 89: 3367-71.
4. Bratt O: Hereditary prostate cancer: clinical aspects. J Urol. 2002; 168: 906-13.
5. Azzouzi AR, Valeri A, Cormier L, Fournier G, Mangin P, Cussenot O: Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. Urology. 2003; 61: 1193-7.
6. Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA: Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol. 1997; 15: 1478-80.
7. Kotsis SV, Spencer SL, Peyser PA, Montie JE, Cooney KA: Early onset prostate cancer: predictors of clinical grade. J Urol. 2002; 167: 1659-63.
8. Grönberg H, Damber L, Tavelin B, Damber JE: No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol. 1998; 82: 564-7.
9. Norrish AE, McRae CU, Cohen RJ, Jackson RT: A population-based study of clinical and pathological prognostic characteristics of men with familial and sporadic prostate cancer. BJU Int. 1999; 84: 311-5.
10. Catalona WJ, Antenor JA, Roehl KA, Moul JW. Screening for prostate cancer in high risk populations. J Urol. 2002; 168: 1980-3; discussion 1983-4.
11. Aprikian AG, Bazinet M, Plante M, Meshref A, Trudel C, Aronson S, et al.: Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol. 1995; 154: 404-6.
12. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, et al.: Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993; 150: 797-802.
13. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, Ramirez EI: Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J Urol. 1995; 154: 1808-12.
14. Sanchez-Ortiz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA, Pettaway CA: African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer. 2006; 107: 75-82.
15. Troncoso P, Babaian RJ, Ro JY, Grignon DJ, von Eschenbach AC, Ayala AG: Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens. Urology. 1989; 34(6 Suppl): 52-6.
16. Gleason D: Histologic grading and clinical staging of prostate carcinoma. In: Tannenbaum M (ed.), Urologic Pathology. The Prostate. Philadelphia, Lea & Febiger. 1977: pp. 171-97.
17. Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P: A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol. 2003; 27: 1291-301.
18. Crawford ED: Epidemiology of prostate cancer. Urology. 2003; 62(6 Suppl1): 3-12.
19. Nelson BA, Shappell SB, Chang SS, Wells N, Farnham SB, Smith JA Jr, et al.: Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2006; 97: 1169-72.
20. Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ: Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998; 160: 437-42.
21. Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI: Pathological features of hereditary prostate cancer. J Urol. 1995; 153: 987-92.
22. Ray ME, Dunn RL, Cooney KA, Sandler HM: Family history of prostate cancer and relapse after definitive external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2003; 57: 371-6.
23. Narod SA, Dupont A, Cusan L, Diamond P, Gomez JL, Suburu R, et al.: The impact of family history on early detection of prostate cancer. Nat Med. 1995; 1: 99-101.
24. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al.: Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004; 22: 439-45.
25. Rohrmann S, Roberts WW, Walsh PC, Platz EA: Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer. Prostate. 2003; 55: 140-6.